Q-omics provides the consensus-scored RPS6KA6 profile across patient tissues and cancer cell-line models. RPS6KA6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RPS6KA6 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, RPS6KA6 RNA expression shows 18,426 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LUAD, KIRC, and KIRP as cancer lineages where RPS6KA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS6KA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS6KA6 survival associations across molecular data types. RPS6KA6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS6KA6 RNA expression–survival associations across cancer types. High RPS6KA6 expression shows unfavorable associations in LUAD, UCEC and LUSC, but favorable associations in BRCA, KIRC and LGG. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RPS6KA6 RNA expression.
This table summarizes RPS6KA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPS6KA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS6KA6 shows lower tumor expression in KIRC, THCA, COAD, STAD, HNSC and KIRP. The KIRC box plot shows higher RPS6KA6 RNA expression in normal versus tumor tissue (log2 FC = −2.881, t-test p < 0.001).
This table shows molecular features associated with RPS6KA6 in patient tissues and cancer cell lines. In patient samples, RPS6KA6 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS6KA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
